$APO

SoftBank and Apollo Global Management Discuss $90 Billion Loan f

Apollo Global Management and SoftBank Group are discussing a loan increase from $5.4B to $9B to support SoftBank's investment in AI firm OpenAI. The loan is backed by SoftBank's Vision Fund 2 assets. Super Micro Computer Inc (SMCI) has a P/S ratio of 0.56, below its historical median, and a GF Score of 84/100, with significant insider selling.

Original reporting
Published Sep 17, 2026, 10:07 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 10:13 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$APO
Bullish
medium confidence
Mentioned
$APO
Relevance
7/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$APOBullishMed
01

Why it matters

The financing could enable SoftBank to capture more AI upside, but adds leverage; Apollo's role may enhance its reputation in tech credit.

02

Market read

A sizable loan discussion that could affect both SoftBank's AI exposure and Apollo's credit profile, with broader implications for AI financing.

03

What to watch

Potential regulatory scrutiny of large AI‑related loans and SoftBank's existing debt load.

Relevance 7/10Novelty 7/10Timing: September 17 2026 (same‑day discussion)

Background

SoftBank seeks additional capital to deepen its stake in OpenAI, while Apollo expands its AI‑focused loan portfolio.

Company-level read

Ticker impact

$APOBullishMedium confidence
Context

Apollo Global Management is negotiating the loan increase for SoftBank, expanding its exposure to AI financing.

Expected impact

Slight positive pressure as the deal showcases Apollo's dealmaking strength.

Evidence & confidence

The deal size is material for Apollo, but details remain pending.

Market effects

Highlights growing financing demand in AI and cloud infrastructure sectors.

May influence Asian tech financing trends and US private‑equity activity.

Signals continued capital flow into AI, relevant for global tech investors.

Counterpoint

If the loan terms prove unfavorable, SoftBank could face balance‑sheet strain, weighing on its stock.

Key entities

  • SoftBank Group Corp.

    Japanese conglomerate pursuing AI investments.

  • Apollo Global Management

    Private‑equity firm providing NAV‑based loans.

Related articles

$APOMed

APO Looks 1.3% Undervalued on GF Value™ Amid Dividend Sustainabi

Apollo Global Management (APO) announced a 30% stake sale in Miller Homes to Daiwa House, aiming to boost production from 5,000 to 7,000 homes annually. APO shares rose 2.2% premarket. The company offers a 1.72% dividend yield, a 49% payout ratio, and a 7.7% 3-year dividend growth rate. APO is trading 1.3% below its GF Value™ of $126.11, with a GF Score™ of 77/100. Insiders and gurus have been net sellers recently.

$ORCLHighAI 8/10

Monday's Stock to Watch: Oracle, Blue Owl, and Apollo

Oracle (ORCL) announced an additional $700M restructuring charge due to layoffs, potentially impacting its stock. Blue Owl (OWL) saw a 10.81% drop in stock value, closing at $10.56, amid loan write-down concerns. Apollo (APO) is in talks to acquire J&J’s (JNJ) orthopedics unit, with mixed performance in the medical devices sector.

$APOHighAI 9/10

Apollo and J&J Face a High-Stakes Orthopedics Deal

Apollo Global (APO) is in talks to acquire J&J's (JNJ) DePuy Synthes orthopedics business for around $20B, according to Bloomberg. J&J generated $9.3B in revenue from the unit in 2025. Both companies could benefit, with Apollo gaining a large medical-device franchise and J&J accelerating its portfolio transformation.

$JNJHighAI 9/10

Why is Johnson & Johnson stock climbing today?

Johnson & Johnson (JNJ) stock rose 1.4% in pre-market trading after reports that Apollo Global Management is in talks to acquire its orthopedics division, DePuy Synthes, for around $20 billion. JNJ had planned to separate the division by October 2025. The company is also presenting at the Morgan Stanley Global Healthcare Conference and shared positive Phase 3 data for its lung cancer drug Rybrevant. The broader U.S. market is down, but JNJ's gain is driven by company-specific news.